AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabolic Stress

Study Background and Research Question

Metabolic and oxidative stresses are hallmark features of the tumor microenvironment, arising from nutrient deprivation and chronic inflammation. Tumor cells, particularly in non-small cell lung cancer (NSCLC), frequently harbor mutations in STK11/LKB1 and KEAP1, genes that regulate energy homeostasis and antioxidant responses, respectively. The crosstalk between the STK11-AMPK (AMP-activated protein kinase) pathway and the KEAP1-NFE2L2/NRF2 axis is thought to be crucial for cell survival under stress. However, the mechanistic details of how these pathways interact, particularly in the context of co-occurring mutations or metabolic adaptation, have not been fully elucidated. The reference study addresses this gap by investigating the molecular feedback loops that link energy sensing, autophagy, and antioxidant defense.

Key Innovation from the Reference Study

The pivotal discovery in this work is a double-positive feedback loop between AMPK and SQSTM1/p62—a scaffold protein that regulates selective autophagy and cellular stress responses. The authors demonstrate that metabolic stress not only increases SQSTM1/p62 expression and phosphorylation but also relies on SQSTM1 activity for full AMPK and NFE2L2/NRF2 activation. Conversely, AMPK activity is required for metabolic stress-induced upregulation and phosphorylation of SQSTM1, creating a mutually reinforcing circuit. This dual activation mechanism enables tumor cells to enhance both energy management and antioxidant defenses, providing a molecular explanation for the frequent co-occurrence of STK11 and KEAP1 mutations in NSCLC and suggesting new therapeutic strategies targeting this feedback system.

Methods and Experimental Design Insights

The research employed a comprehensive suite of cellular and molecular techniques to dissect the feedback between AMPK and SQSTM1. Key elements of the experimental design included:

• Induction of metabolic stress through glucose deprivation and chemical inhibitors.
• Assessment of AMPK and NFE2L2 activity using phosphorylation-specific antibodies, reporter assays, and immunoprecipitation.
• Manipulation of SQSTM1 expression via CRISPR and RNAi approaches in mouse embryonic fibroblasts (MEFs) and human cancer cell lines.
• Analysis of macroautophagic degradation of KEAP1 and the assembly of the AXIN–STK11–AMPK complex on lysosomal membranes.
• Use of pharmacological agents to probe the roles of lysosomal pH, calcium flux, and ROS in SQSTM1 phosphorylation.

Notably, the study integrated time-course and dose-response experiments to delineate causality and sequence within the feedback loop. The functional relevance of SQSTM1 phosphorylation sites (S24 and S226) was validated through site-directed mutagenesis and rescue assays.

Core Findings and Why They Matter

The principal findings, as detailed in the reference article, can be summarized as follows:

• Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62. Activation of AMPK upregulates and phosphorylates SQSTM1, which in turn further stimulates AMPK activity. This feedback is essential for robust metabolic adaptation.
• Dual activation of AMPK and NFE2L2/NRF2 synergizes antioxidant defense. SQSTM1-driven autophagic degradation of KEAP1 releases NFE2L2, promoting antioxidant gene expression and tumor survival under stress.
• Lysosomal pH and calcium signaling are integral to the feedback loop. AMPK-dependent reduction in lysosomal proton concentration leads to TFEB/TFE3 dephosphorylation (via PP2A), upregulating SQSTM1 expression. Additionally, ROS and pH-dependent secretion of lysosomal Ca²⁺ activate MAP3K7/TAK1, driving SQSTM1 phosphorylation at S24 and S226—sites critical for feedback function.
• Physiological implications for cancer evolution. The feedback loop explains why tumor cells with both STK11 and KEAP1 mutations are selected for, as dual pathway activation supports both energy homeostasis and oxidative stress resistance.

These insights advance our mechanistic understanding of how cancer cells integrate metabolic and redox signaling, and they provide a rationale for targeting the AMPK–SQSTM1–NFE2L2 axis in metabolic and oxidative stress-related pathologies.

Comparison with Existing Internal Articles

This research builds upon and extends the mechanistic frameworks established in internal reviews focused on calcium signaling and endoplasmic reticulum (ER) stress responses. For example, the article "Thapsigargin: Precision SERCA Pump Inhibitor for Calcium Signaling" emphasizes the use of SERCA pump inhibition to provoke ER stress and modulate apoptosis assays, which intersects with the current study's focus on lysosome-mediated stress adaptation. Similarly, "Thapsigargin: Precision SERCA Inhibition for ER Stress Mechanisms" discusses how chemical perturbation of calcium homeostasis via thapsigargin can be leveraged to dissect ER stress and cell fate decisions. The reference study advances these concepts by showing that metabolic and lysosomal stress converge on a feedback circuit linking AMPK, SQSTM1, and NFE2L2, thus providing a broader context for the use of SERCA inhibitors and related tools in mechanistic pathway analysis.

Limitations and Transferability

While the study provides compelling evidence for the AMPK–SQSTM1 feedback loop in cultured cells and supports its relevance to tumor evolution, several limitations should be considered:

• Cell line dependency: Most experiments were conducted in MEFs and cancer cell lines; primary cells or in vivo models may yield additional insights into tissue-specific regulation.
• Pharmacological specificity: Some chemical inhibitors used (e.g., for lysosomal pH or calcium modulation) may have off-target effects, necessitating additional genetic or orthogonal validation.
• Clinical translation: While the feedback mechanism provides a rationale for targeting the AMPK–SQSTM1–NFE2L2 axis, further studies are required to assess its therapeutic potential and safety in human disease models.

Nonetheless, the core findings are likely transferable to other contexts of metabolic and oxidative stress, including neurodegenerative disease models and advanced apoptosis assays, given the conserved nature of the pathways involved.

Protocol Parameters

• Metabolic stress induction: Glucose deprivation for 2–24 hours or use of metabolic inhibitors such as 2-deoxyglucose at 5–10 mM to mimic nutrient starvation.
• AMPK activation assay: Immunoblotting for phosphorylated AMPK (Thr172) following stress induction, with or without SQSTM1 modulation.
• SQSTM1/p62 manipulation: CRISPR-mediated knockout or siRNA knockdown, plus rescue with wild-type or phosphorylation-site mutants (S24A/S226A) for mechanistic studies.
• Assessment of antioxidant response: NFE2L2/NRF2 target gene expression via qPCR or reporter assays after stress and genetic/pharmacological interventions.
• Use of SERCA pump inhibitors: Thapsigargin (typically 10–500 nM) can be applied for 15–60 minutes to provoke ER/lysosomal calcium release and stress for downstream pathway analysis, as per product recommendations.

Research Support Resources

For researchers aiming to dissect calcium signaling pathways, endoplasmic reticulum stress responses, or apoptosis mechanisms in line with this study's workflows, Thapsigargin (SKU B6614) from APExBIO is a validated SERCA pump inhibitor widely used to robustly disrupt intracellular calcium homeostasis. Its nanomolar potency and reproducibility make it suitable for modeling stress responses and validating feedback circuits involving AMPK, SQSTM1, and NFE2L2/NRF2. For practical assay design and protocol details, consult the internal article on Thapsigargin in calcium signaling or benchmarked SERCA inhibition protocols.